CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.
March 11th 2019
After a review of more than 600,000 people, researchers discovered an association between foods consumed and bladder cancer risk.
February 22nd 2019
Using tumor DNA found in urine, researchers believe they have found a method to diagnose and monitor bladder cancer that outperforms standard tests.
February 21st 2019
After patients with non–muscle invasive bladder cancer fail to respond to treatment with BCG immunotherapy, Keytruda (pembrolizumab) may induce responses in these high-risk patients.
February 20th 2019
Vofatamab (B-701) may be safe and effective for patients with locally advanced or metastatic bladder cancer with an FGFR3 mutation who have relapsed after, or are refractory to, at least one prior line of chemotherapy, according to preliminary findings.
February 13th 2019
An integrative model helped to determine which patients with bladder cancer may benefit from checkpoint inhibitor therapy.
January 18th 2019
Although chemotherapy and radical cystectomy are traditionally used to treat muscle-invasive disease, a recent analysis shows similar overall survival outcomes in patients treated with chemoradiotherapy.
January 18th 2019
Older adults may be at an increased risk for a heart attack or stroke five months before they are even diagnosed with cancer – a risk that peaked in the month prior to diagnosis, according to a report published in Blood.
January 10th 2019
A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.
November 29th 2018
While the treatment landscape continues to grow in bladder cancer, researchers should continue to follow the evidence, but accrual of patients in clinical trials is also key, according to Petros Grivas, M.D., Ph.D.
November 27th 2018
Patients with muscle-invasive bladder cancer who were treated with a dose-dense regimen of neoadjuvant chemotherapy followed by radical cystectomy (surgery to remove the urinary bladder) experienced more complete responses to treatment compared with the current standard of neoadjuvant chemotherapy.
November 26th 2018
The treatment paradigm for bladder cancer has been quite exciting in the last few years, and even more is yet to come, according to Petros Grivas, M.D., Ph.D.
November 26th 2018
Although immunotherapies show promise for patients, there are still challenges ahead.
November 6th 2018
Patients with platinum-pretreated metastatic urothelial carcinoma who were treated with a higher dosage of Yervoy (ipilimumab) in combination with Opdivo (nivolumab) experienced improved survival and tolerable side effects, according to findings from the phase 1/2 CheckMate-032 trial.
October 25th 2018
The immunotherapy agent Keytruda is showing promise for treating non-muscle invasive bladder cancer, according to a recent study.
October 23rd 2018
In a recent survey, individuals in remission reported a more positive experience with bladder cancer compared with their counterparts who currently have active disease.
October 22nd 2018
While universal screening for Lynch syndrome is currently only recommended for patients with colorectal and endometrial cancers, a new study recently published in The American Journal of Surgical Pathology suggests this for patients with upper tract urothelial carcinoma, too.
October 8th 2018
Can providers decrease opioid prescriptions after surgery, while still managing care adequately?
October 5th 2018
Immunotherapy has been a buzzworthy topic in the field of bladder cancer over the last couple of years. However, according to a Food and Drug Administration (FDA) safety warning, patients with metastatic disease may need to have their treatment altered.
October 2nd 2018
Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.
September 27th 2018
Researchers determined that the use of methotrexate, vinblastine, doxorubicin and cisplatin before cystectomy may induce better outcomes for patients with advanced bladder cancer.
September 26th 2018
A new test that identifies which bladder cancer tumors will become invasive could help reduce health care costs and over-treatment in patients.
September 3rd 2018
Stromal cells – known to provide structure to one’s organs – found in bladder cancer may explain why some patients do not respond to Opdivo (nivolumab) treatment.
September 1st 2018
Some patients eligible for bladder surgery due to cancer may safely opt to preserve the organ.
August 31st 2018
After chemotherapy, immunotherapy has become the standard treatment for bladder cancer. Will it ever play a bigger role?
August 30th 2018
While there is currently no definitive way to predict who will respond and who will not, researchers at Brighton and Sussex Medical School in the United Kingdom are working on a blood test that could identify about half of those who may not.
August 23rd 2018
CURE spoke with Matthew Mossanen, M.D., from the Division of Urology at Brigham and Women’s Hospital, about what Bacillus Calmette-Guérin (BCG) is and what patients should know about this treatment option.
August 17th 2018
The Food and Drug Administration (FDA) updated the prescribing information for two immunotherapy agents – Keytruda (pembrolizumab) and Tecentriq (atezolizumab) – approved to treat patients with locally advanced or metastatic bladder cancer who are not eligible for cisplatin-based therapy.
July 31st 2018
With five immunotherapy drugs approved in the bladder cancer space, the next question researchers find themselves asking is whether these drugs would work better alone or as part of a combination for patients with metastatic disease.
July 28th 2018
Creating a medical family tree is helpful. If cancer is common, noting which branches include it can help inform decisions.